Brokerages expect China Biologic Products Holdings, Inc. (NASDAQ:CBPO) to announce earnings per share (EPS) of $1.11 for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for China Biologic Products’ earnings. China Biologic Products posted earnings per share of $0.95 in the same quarter last year, which would suggest a positive year-over-year growth rate of 16.8%. The company is scheduled to announce its next quarterly earnings report on Thursday, February 22nd.
According to Zacks, analysts expect that China Biologic Products will report full-year earnings of $5.22 per share for the current financial year, with EPS estimates ranging from $5.17 to $5.26. For the next year, analysts forecast that the firm will post earnings of $5.75 per share, with EPS estimates ranging from $5.49 to $6.00. Zacks’ earnings per share averages are an average based on a survey of research analysts that follow China Biologic Products.
A number of research firms recently commented on CBPO. Zacks Investment Research upgraded shares of China Biologic Products from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. BidaskClub upgraded shares of China Biologic Products from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $137.50.
China Biologic Products (CBPO) traded down $0.32 during trading hours on Friday, reaching $78.77. 67,989 shares of the company were exchanged, compared to its average volume of 150,438. China Biologic Products has a 52 week low of $72.21 and a 52 week high of $120.46. The company has a market cap of $2,183.62, a price-to-earnings ratio of 19.84, a P/E/G ratio of 1.29 and a beta of 1.78.
A number of institutional investors have recently modified their holdings of the business. AXA increased its position in China Biologic Products by 35.9% during the 3rd quarter. AXA now owns 128,220 shares of the biopharmaceutical company’s stock valued at $11,831,000 after purchasing an additional 33,886 shares during the period. California Public Employees Retirement System increased its position in China Biologic Products by 51.7% during the 3rd quarter. California Public Employees Retirement System now owns 44,757 shares of the biopharmaceutical company’s stock valued at $4,130,000 after purchasing an additional 15,257 shares during the period. Cubist Systematic Strategies LLC increased its position in China Biologic Products by 73.2% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 4,617 shares of the biopharmaceutical company’s stock valued at $426,000 after purchasing an additional 1,952 shares during the period. Cornerstone Capital Management Holdings LLC. increased its position in China Biologic Products by 31.0% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 363,190 shares of the biopharmaceutical company’s stock valued at $33,511,000 after purchasing an additional 85,909 shares during the period. Finally, Temasek Holdings Private Ltd purchased a new position in China Biologic Products during the 3rd quarter valued at $3,414,000. 65.13% of the stock is currently owned by institutional investors and hedge funds.
About China Biologic Products
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.